Clinical trial
everlinQ Endovascular Access Systems Enhancements (EASE-2) Study
NCT03708562 is registered in ClinicalTrials.gov with C. R. Bard as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- everlinQ Endovascular Access Systems Enhancements (EASE-2) Study
- Lead sponsor
- C. R. Bard
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- October 16, 2017
- Completion date
- December 12, 2018
- Enrollment
- 24 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic kidney diseases